PCN47 COSTS OF TREATING SEVERE ADVERSE EVENTS OBSERVED WITH A REGIMEN OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74298-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)74298-4/fulltext
Title :
PCN47 COSTS OF TREATING SEVERE ADVERSE EVENTS OBSERVED WITH A REGIMEN OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74298-4&doi=10.1016/S1098-3015(10)74298-4
First page :
Section Title :
Open access? :
No
Section Order :
226